Salts of nitrogen-containing heterocyclic compound, and solid forms of salts, pharmaceutical composition and use thereof

A crystal form of a salt of a compound of formula (I),

• (R)-2-((1-(1H-1,2,3-triazol-5-yl)propan-2-yl)oxy)-1-(2-((2,3-dihydro-1 H-inden-2-yl)amino)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)ethan-1-one
• wherein the crystal form is a crystal form A of hydrochloride of the compound of formula (I), wherein the crystal form A of hydrochloride has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 7.48±0.20°, 13.13±0.20°, 16.47±0.20° and 23.94±0.20°;
• wherein the crystal form is a crystal form A of sulfate of the compound of formula (I), wherein the crystal form A of sulfate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 5.49±0.20°, 15.88±0.20°, 17.48±0.20° and 22.40±0.20°;
• wherein the crystal form is a crystal form A of maleate of the compound of formula (I), wherein the crystal form A of maleate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 4.43±0.20°, 13.86±0.20°, 14.41±0.20°, 15.00±0.20°, 22.07±0.20°, 22.65±0.20°, 25.58±0.20° and 27.34±0.20°;
• wherein the crystal form is a crystal form A of phosphate of the compound of formula (I), wherein the crystal form A of phosphate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 5.08±0.20°, 15.93±0.20°, 24.37±0.20° and 25.19±0.20°;
• wherein the crystal form is a crystal form A of tartrate of the compound of formula (I), wherein the crystal form A of tartrate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 5.00±0.20° and 15.88±0.20°;
• wherein the crystal form is a crystal form B of tartrate of the compound of formula (I), wherein the crystal form B of tartrate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 5.24±0.20° and 23.94±0.20°;
• wherein the crystal form is a crystal form C of tartrate of the compound of formula (I), wherein the crystal form C of tartrate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 4.60±0.20°, 16.15±0.20° and 18.13±0.20°;
• wherein the crystal form is a crystal form A of fumarate of the compound of formula (I), wherein the crystal form A of fumarate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 9.52±0.20°, 13.29±0.20°, 14.92±0.20° and 25.23±0.20°;
• wherein the crystal form is a crystal form A of citrate of the compound of formula (I), wherein the crystal form A of citrate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 4.96±0.20° and 15.76±0.20°;
• wherein the crystal form is a crystal form A of glycolate of the compound of formula (I), wherein the crystal form A of glycolate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 5.26±0.20°, 7.27±0.20°, 14.12±0.20°, 16.02±0.20° and 24.11±0.20°;
• wherein the crystal form is a crystal form A of succinate of the compound of formula (I), wherein the crystal form A of succinate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 5.26±0.20°, 14.00±0.20°, 15.76±0.20°, 21.07±0.20°, 22.00±0.20° and 27.08±0.20°;
• wherein the crystal form is a crystal form B of succinate of the compound of formula (I), wherein the crystal form B of succinate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 9.54±0.20°, 12.60±0.20°, 14.91±0.20°, 19.17±0.20°, 21.02±0.20° and 24.88±0.20°;
• wherein the crystal form is a crystal form B of adipate of the compound of formula (I), wherein the crystal form B of adipate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 4.98±0.20°, 10.69±0.20°, 13.88±0.20°, 21.41±0.20°, 24.97±0.20° and 26.15±0.20°;
• wherein the crystal form is a crystal form A of sebacate of the compound of formula (I), wherein the crystal form A of sebacate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 4.57±0.20°, 9.27±0.20°, 11.20±0.20°, 14.40±0.20°, 20.16±0.20°, 24.63±0.20° and 26.73±0.20°;
• wherein the crystal form is a crystal form A of p-toluenesulfonate of the compound of formula (I), wherein the crystal form A of p-toluenesulfonate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 6.04±0.20°, 8.59±0.20°, 14.27±0.20°, 17.14±0.20° and 25.29±0.20°;
• wherein the crystal form is a crystal form A of benzenesulfonate of the compound of formula (I), wherein the crystal form A of benzenesulfonate has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 6.16±0.20°, 8.98±0.20°, 14.22±0.20°, 16.90±0.20°, 18.31±0.20°, 20.92±0.20°, 25.11±0.20° and 26.29±0.20°;
• wherein the crystal form is a crystal form A of hydrobromide of the compound of formula (I), wherein the crystal form A of hydrobromide has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 9.54±0.20° and 24.63±0.20°;
• or
• wherein the crystal form is a crystal form B of hydrobromide of the compound of formula (I), wherein the crystal form B of hydrobromide has characteristic peaks in an X-ray powder diffraction pattern using Cu-Kα radiation at the following 2θ angles:
• 9.48±0.20°, 15.89±0.20° and 23.98±0.20°.